Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dl-Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | XIAP | P98170 | 1/20 | 0.59 |
| ▸ | CTSC | P53634 | 2/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 3/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.45 |
| ▸ | FAP | Q12884 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylalanine SCHEMBL148429 | 1.00 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL22468204 | 1.00 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL28136484 | 1.00 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP | |
| D-Phenylalanine SCHEMBL2184336 | 1.00 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL2478802 | 1.00 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL2478801 | 1.00 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL5134569 | 1.00 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL21899689 | 0.95 | SLC7A5 (0.54) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL4405170 | 0.95 | SLC7A5 (0.54) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL21899690 | 0.95 | SLC7A5 (0.54) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734541-B1 | NOVEL IL-17R-ECD MUTANTS | THE NAT INST FOR BIOTECHNOLOGY IN THE NEGEV LTD (IL) | 2017-09-06 | — | — | EP | claimed |
| CN-102837341-B | Mildew-proof and mothproof treatment method for bamboo materials | UNIV CENTRAL SOUTH FORESTRY | 2014-08-13 | — | — | CN | claimed |
| EP-1768490-A2 | SYSTEMS AND METHODS FOR EX-VIVO ORGAN CARE | Transmedics, Inc. (US) | 2007-04-04 | — | — | EP | claimed |
| EP-1575642-A4 | MULTI-BALLOON CATHETER WITH HYDROGEL COATING | BOSTON SCIENT LTD (BB) | 2007-03-07 | — | — | EP | claimed |
| WO-2006042138-A2 | SYSTEMS AND METHODS FOR EX-VIVO ORGAN CARE | TRANSMEDICS, INC. (US) | 2006-04-20 | — | — | WO | claimed |
| EP-1575642-A2 | MULTI-BALLOON CATHETER WITH HYDROGEL COATING | Boston Scientific Limited (BB) | 2005-09-21 | — | — | EP | claimed |
| WO-2004028587-A2 | MULTI-BALLOON CATHETER WITH HYDROGEL COATING | BOSTON SCIENTIFIC LIMITED (BB) | 2004-04-08 | — | — | WO | claimed |
| EP-0139592-B1 | PROCESS AND APPARATUS FOR THE PRODUCTION OF AMINOACIDS BY FERMENTATION | LES PRODUITS ORGANIQUES DU SANTERRE ORSAN (FR) | 1992-03-25 | — | — | EP | claimed |
| CN-118340216-A | Medicinal and edible plant composition with uric acid reducing function and preparation method and application thereof | 湖南楚茗茶业有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118043316-A | Factor XIIa inhibitors | 卢纳克治疗有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4347578-A1 | FACTOR XIIA INHIBITORS | Lunac Therpeutics Ltd (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
| EP-3773555-A1 | FACTOR XIIA INHIBITORS | University of Leeds (GB) | 2021-02-17 | — | — | EP | disclosed |
| CN-112165938-A | Factor XIIA inhibitors | 利兹大学 | 2021-01-01 | — | — | CN | disclosed |
| WO-1998029547-A1 | MODULATORS OF RADIAL GLIA-ASTROCYTE DIFFERENTIATION AND TRANSFORMATION, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 1998-07-09 | — | — | WO | disclosed |
| US-5185248-A | Farnesylation of peptide substrate; detecting amount of labeled farnesyl residue in substrate | E. R. SQUIBB & SONS, INC. (US) | 1993-02-09 | — | — | US | disclosed |
| WO-1990007713-A1 | MOLECULAR RECOGNITION UNITS | CYTOGEN CORPORATION (US) | 1990-07-12 | — | — | WO | disclosed |
| US-4590178-A | DIURETICS | AJINOMOTO COMPANY, INCORPORATED (JP) | 1986-05-20 | — | — | US | disclosed |
| US-4536395-A | DIPEPTIDES | AJINOMOTO CO., INC. (JP) | 1985-08-20 | — | — | US | disclosed |
| US-4472381-A | Amino acid derivatives, methods of preparing said derivatives and antihypertensive drugs containing them | AJINOMOTO COMPANY INCORPORATED (JP) | 1984-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | SLC7A5 4624/4885PTGS1 660/4885ALPI 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.